UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Annals of oncology, 2019-03, Vol.30 (3), p.397-404

2019

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Annals of oncology, 2019-03, Vol.30 (3), p.405-411

2019

Link zum Volltext

Verfügbarkeit prüfen

Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086

Annals of oncology, 2017-09, Vol.28, p.v608-v608

2017

Link zum Volltext

Verfügbarkeit prüfen

508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041)

European journal of cancer (1990), 2014-11, Vol.50, p.165-166

2014

Link zum Volltext

Verfügbarkeit prüfen

PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later

Annals of oncology, 2021-12, Vol.32 (12), p.1460-1462

2021

Link zum Volltext

Verfügbarkeit prüfen

Characterizing mechanisms of resistance to BRAF and MEK inhibitors in cancers with Class 2 BRAF mutations: uncovering novel therapeutic opportunities

European journal of cancer (1990), 2022-10, Vol.174, p.S63-S64

2022

Link zum Volltext

Verfügbarkeit prüfen

LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

Annals of oncology, 2023-10, Vol.34, p.S1260-S1261

2023

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2– breast cancer: Results from the phase 3 KEYNOTE-756 study

European journal of cancer (1990), 2024-03, Vol.200, p.113608, Article 113608

2024

Link zum Volltext

Verfügbarkeit prüfen

LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial

Annals of oncology, 2023-10, Vol.34, p.S1264-S1265

2023

Link zum Volltext

Verfügbarkeit prüfen

CCTG IND.231: A phase 1 trial evaluating CX-5461 in patients with advanced solid tumors

Annals of oncology, 2018-03, Vol.29, p.iii8-iii8

2018

Link zum Volltext

Verfügbarkeit prüfen

164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355

Annals of oncology, 2022-05, Vol.33, p.S197-S198

2022

Link zum Volltext

Verfügbarkeit prüfen

68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC

Annals of oncology, 2020-11, Vol.31, p.S1268-S1268

2020

Link zum Volltext

Verfügbarkeit prüfen

43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia

Annals of oncology, 2020-11, Vol.31, p.S1257-S1257

2020

Link zum Volltext

Verfügbarkeit prüfen

356TiP A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009

Annals of oncology, 2020-09, Vol.31, p.S392-S392

2020

Link zum Volltext

Verfügbarkeit prüfen

LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

Annals of oncology, 2021-09, Vol.32, p.S1289-S1290

2021

Link zum Volltext

Verfügbarkeit prüfen

531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial

Annals of oncology, 2021-09, Vol.32, p.S596-S596

2021

Link zum Volltext

Verfügbarkeit prüfen

19O A phase Ib trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative (HER2-) breast cancer (aBC)

Annals of oncology, 2020-03, Vol.31, p.S7

2020

Link zum Volltext

Verfügbarkeit prüfen

KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer

Annals of oncology, 2019-11, Vol.30, p.ix7-ix8

2019

Link zum Volltext

Verfügbarkeit prüfen

57P Intrinsic and acquired blood-based tumor mutational burden in metastatic ER+/HER2- breast cancer treated with endocrine therapy and a CDK4/6-inhibitor

ESMO open, 2024-05, Vol.9, p.103064, Article 103064

2024

Link zum Volltext

Verfügbarkeit prüfen

45P Integrated multi-omic analysis of HR+/HER2- breast cancer cell lines resistant to CDK4/6 inhibitors

ESMO open, 2024-05, Vol.9, p.103052, Article 103052

2024

Link zum Volltext

Verfügbarkeit prüfen

261TiP TROPION-Breast05: Phase (Ph) III study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

ESMO open, 2024-05, Vol.9, p.103282, Article 103282

2024

Link zum Volltext

Verfügbarkeit prüfen

191MO KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumab and in patients with immune-mediated AEs

ESMO open, 2023-05, Vol.8 (1), p.101380, Article 101380

2023

Link zum Volltext

Verfügbarkeit prüfen

LBA2 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC): Additional safety analysis from TROPION-Breast01

ESMO open, 2024-05, Vol.9, p.103479, Article 103479

2024

Link zum Volltext

Verfügbarkeit prüfen

198P Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: Patient-reported outcomes from KEYLYNK-009

ESMO open, 2024-05, Vol.9, p.103220, Article 103220

2024

Link zum Volltext

Verfügbarkeit prüfen

Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer

Annals of oncology, 2010-07, Vol.21 (7), p.1411-1418

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Oncology
(5)
Female
(3)
Hematology
(3)
Humans
(3)
Neoplasm Metastasis
(3)
Adult
(2)
Aged
(2)
Aged, 80 And Over
(2)
Anti-Pd-1
(2)
Antibodies, Monoclonal, Humanized - Administration & Dosage
(2)
Antibodies, Monoclonal, Humanized - Adverse Effects
(2)
B7-H1 Antigen - Genetics
(2)
Cohort Studies
(2)
Gene Expression Regulation, Neoplastic - Drug Effects
(2)
Immunotherapy
(2)
Life Sciences & Biomedicine
(2)
Male
(2)
Middle Aged
(2)
Pembrolizumab
(2)
Progression-Free Survival
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(22)
Journals@Ovid Complete
(16)
IngentaConnect
(5)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(3)
MEDLINE
(3)
Elsevier ScienceDirect Journals Complete
(3)
IngentaConnect Journals
(1)

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086

508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041)

PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later

Characterizing mechanisms of resistance to BRAF and MEK inhibitors in cancers with Class 2 BRAF mutations: uncovering novel therapeutic opportunities

LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

Neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2– breast cancer: Results from the phase 3 KEYNOTE-756 study

LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial

CCTG IND.231: A phase 1 trial evaluating CX-5461 in patients with advanced solid tumors

164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355

68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC

43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia

356TiP A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009

LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial

19O A phase Ib trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative (HER2-) breast cancer (aBC)

KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer

57P Intrinsic and acquired blood-based tumor mutational burden in metastatic ER+/HER2- breast cancer treated with endocrine therapy and a CDK4/6-inhibitor

45P Integrated multi-omic analysis of HR+/HER2- breast cancer cell lines resistant to CDK4/6 inhibitors

261TiP TROPION-Breast05: Phase (Ph) III study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

191MO KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumab and in patients with immune-mediated AEs

LBA2 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC): Additional safety analysis from TROPION-Breast01

198P Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: Patient-reported outcomes from KEYLYNK-009

Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer

Suchergebnisse filtern